ArticleProceedings of the National Academy of Sciences of the United States of America2009
Isolation of a cellular factor that can reactivate latent HIV-1 without T cell activation.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- A targeted CRISPR screen identifies ETS1 as a regulator of HIV-1 latency.PLoS pathogens · 2025Article
- Integrated Single-cell Multiomic Analysis of HIV Latency Reversal Reveals Novel Regulators of Viral Reactivation.Genomics, proteomics & bioinformatics · 2024Article
- Filgotinib suppresses HIV-1-driven gene transcription by inhibiting HIV-1 splicing and T cell activation.The Journal of clinical investigation · 2020Article
- Current views on HIV-1 latency, persistence, and cure.Folia microbiologica · 2017Review
- Heat Shock Protein 90 Facilitates Latent HIV Reactivation through Maintaining the Function of Positive Transcriptional Elongation Factor b (p-TEFb) under Proteasome Inhibition.The Journal of biological chemistry · 2016Article
- The two sides of Tat.eLife · 2016Article
- MARCH8 inhibits HIV-1 infection by reducing virion incorporation of envelope glycoproteins.Nature medicine · 2015Article
- An enhanced chimeric firefly luciferase-inspired enzyme for ATP detection and bioluminescence reporter and imaging applications.Analytical biochemistry · 2015Article
- Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure.Cell · 2013Article
- HIV-1 transcription and latency: an update.Retrovirology · 2013Review
- Quantitative phosphoproteomics reveals extensive cellular reprogramming during HIV-1 entry.Cell host & microbe · 2013Article
- Antibody-based candidate therapeutics against HIV-1: implications for virus eradication and vaccine design.Expert opinion on biological therapy · 2013Review
- Cyclin T1 and CDK9 T-loop phosphorylation are downregulated during establishment of HIV-1 latency in primary resting memory CD4+ T cells.Journal of virology · 2013Article
- Calcium/calcineurin synergizes with prostratin to promote NF-κB dependent activation of latent HIV.PloS one · 2013Article
- Human immunodeficiency virus (HIV) latency: the major hurdle in HIV eradication.Molecular medicine (Cambridge, Mass.) · 2012Review
- Deployment of the human immunodeficiency virus type 1 protein arsenal: combating the host to enhance viral transcription and providing targets for therapeutic development.The Journal of general virology · 2012Article
- Molecular Understanding of HIV-1 Latency.Advances in virology · 2012Article
- HIV reservoirs and latency models.Virology · 2011Review
- NF-κB/Rel: agonist and antagonist roles in HIV-1 latency.Current opinion in HIV and AIDS · 2011Review
- Studies of HIV-1 latency in an ex vivo model that uses primary central memory T cells.Methods (San Diego, Calif.) · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
HIV-1 latency in resting CD4(+) T cells represents a major barrier to virus eradication in patients on highly active antiretroviral therapy (HAART). Eliminating the latent HIV-1 reservoir may require the reactivation of viral gene expression in latently infected cells. Most approaches for reactivating latent HIV-1 require nonspecific T cell activation, which has potential toxicity. To identify factors for reactivating latent HIV-1 without inducing global T cell activation, we performed a previously undescribed unbiased screen for genes that could activate transcription from the HIV-1 LTR in an NF-kappaB-independent manner, and isolated an alternatively spliced form of the transcription factor Ets-1, DeltaVII-Ets-1. DeltaVII-Ets-1 activated HIV-1 transcription through 2 conserved regions in the LTR, and reactivated latent HIV-1 in cells from patients on HAART without causing significant T cell activation. Our results highlight the therapeutic potential of cellular factors for the reactivation of latent HIV-1 and provide an efficient approach for their identification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.